Drug companies GSK and Sanofi have said they’re starting clinical trials of their coronavirus vaccine.
The two firms said 440 adults would tend the vaccine at 11 sites within the US.
They hope to possess the primary results of the trial by December and if it’s successful they’re going to advance to further trials by the top of the year.
They join around 20 pharmaceutical companies holding clinical trials within the race to seek out a vaccine.
The partnership between the UK’s GSK and France’s Sanofi uses an equivalent protein-based technology together of Sanofi’s seasonal influenza vaccines.
“The initiation of our clinical study is a crucial step and brings us closer to a possible vaccine which could help defeat Covid-19”, said Thomas Triomphe, executive vice-chairman and global head of Sanofi Pasteur.
“Our dedicated teams and partner still work round the clock as we aim to deliver first leads to early December. Positive data will enable a prompt start of the pivotal phase 3 trial by the top of this year”.
If the third stage trial goes ahead and enough data are collected, the businesses decide to apply for regulatory approval within the half of 2021.
Earlier in the week , drug company AstraZeneca, which is holding advanced clinical trials for the vaccine it’s developing with Oxford University, announced it had made an affect in Oxford Biomedica to reserve production lines at the company’s new factory.
The UK government has ordered 100 million doses of the AstraZeneca vaccine, which is one of around 23 vaccines in clinical trials globally.
It is not yet known which of those experimental vaccines will work.